drugset / Trial / NCT00433615

Clinical Study of R744 to Predialysis Patients

NCT00433615

Phase 3 Completed 124 enrolled Chugai Pharmaceutical
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will assess the efficacy and safety of subcutaneous or intravenous R744 in renal anemia patients on Predialysis.

Timeline

Start
2007-02
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject methoxy polyethylene glycol-epoetin beta Protein / enzyme biologic 25 ug Subcutaneous
Subject methoxy polyethylene glycol-epoetin beta Protein / enzyme biologic 400 ug Subcutaneous

Indications